Valera pairs with Spepharm to market Vantas, Supprelin-LA

By Jennifer Chiou

New York, July 20 - Valera Pharmaceuticals, Inc. announced a partnership with Spepharm Holding BV for the exclusive marketing and distribution rights to Vantas and Supprelin-LA in the European Union, Switzerland and Norway.

Spepharm is a newly created entity backed by TVM Capital and Sanders Morris Harris Inc., life science investment firms.

Vantas is a 12-month implant for the treatment of advanced prostate cancer, which is marketed in the United States.

In June, Valera submitted a New Drug Application to the FDA for Supprelin-LA, a yearlong implant for central precocious puberty.

Valera said that the drug delivery mechanisms for both drugs are based on its Hydron implant technology.

Under the terms of the agreements with the TVM-managed Life Science Ventures VI Fund and the Life Sciences Opportunities Funds managed by Sanders Morris Harris, Valera will own 19.9% of Spepharm and will have part of the company's board.

"Given Spepharm's interest in the European urology and endocrinology specialties, both Vantas and Supprelin-LA represent an excellent fit with our growth strategy," Spepharm chief executive officer Jean-Francois Labbe said in a news release.

Valera is a specialty pharmaceutical company based in Cranbury, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.